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ABSTRACT
Stereotactic body radiotherapy is a highly technology-driven treatment modality. The wider availability of in-room imaging
and advanced radiotherapy delivery techniques has led to more institutions offering stereotactic ablative therapy (SABR).
While some technological challenges remain, the crucial point for the next generation of SABR clinical trials is that today’s
technology is used correctly and close to its optimal potential for accuracy. The credentialing procedure of SABR needs to
be extensive, but this investment will benefit the trial itself, the patients and the professionals involved.
COMMENTARY
Radiotherapy is a highly technology-driven treatment modality
for patients with cancer, and few treatments are as technology
intensive as stereotactic procedures. Yet, technological advances
can move slowly: it took over 15 years from the ﬁrst in-
tracranial stereotactic treatment in the mid-1970s1 to using the
same approach in the thorax and abdomen.2 From its in-
troduction, pioneers of this stereotactic body radiotherapy
[recently also called stereotactic ablative therapy (SABR)] were
aware of the challenges of interfraction and intrafraction
motion mainly due to respiration. The stereotactic body frame
introduced by Lax et al3 had the dual purpose of providing
patient and tumour immobilization as well as an innovative
way to transfer the information of the tumour position from
the pre-treatment CTs to the treatment couch.
Today, in-room imaging has made the veriﬁcation of patient
(and target) position easier and more efﬁcient. Faster treatment
deliveries (volumetric-modulated arc therapy) have also
resulted in a more comfortable procedure, accessible to patients
who are frailer. External reference frames have been replaced by
chest boards and vacuum ﬁxing technology. In addition to the
reliability of the treatment, its cost efﬁciency has made it a
viable alternative to surgery for new patient groups, such as
patients with Stage 1 non-small-cell lung cancer.4
A typical lung SABR treatment in 2005 involved three-
dimensional (3D) planning CT with ﬂuoroscopy, daily
treatment CTs (on rail if available, otherwise in a separate
room) and a stereotactic body frame, possibly with
abdominal compression to reduce respiratory tumour
motion. Today, four-dimensional CT and daily cone-beam
CT are widely available and constitute the state of the art in
thoracic and abdominal treatments, together with robotic
treatment units (such as the CyberKnife) that feature tu-
mour tracking. These imaging capabilities, along with
improvements in dose calculation software, have translated
into a more reliable delivery of the dose to the tumour and
have enabled conﬁrming a clear relationship between
prescribed dose and local control for Stage I non-small-cell
lung cancer.5,6 The wider availability of technology has led
to more and more institutions offering SABR: treatments
are reaching the community hospital setting and are no
longer limited to large academic centres.
While minimal technological requirements are deﬁnitely
needed to ensure a certain quality and consistency of out-
come amongst institutions participating in a clinical trial,
this does not necessarily mean that a multi-institutional trial
should enforce a uniform technological approach. A careful
selection of technological approaches is necessary to achieve
a balance between ensuring a high quality of treatment
delivery and allowing the desired number of institutions to
enter the trial. For example, the new Lungtech trial7 will allow
for gating and tracking as alternatives to a more common
“internal target volume” approach. The already accruing
Radiation Therapy Oncology Group 1112 (NTC01730937)
allows for treatment delivery using 3D conformal radiother-
apy, intensity-modulated radiotherapy or protons for primary
liver cancer. These modalities will lead to different dose
distributions to organs at risk (OARs). However, this can also be an
advantage if one of the end points of the trial is to investigate
toxicity: variations in dose distributions may provide a spread in
data points on which to build a dose–response relationship.
Can technology improve SABR treatments further? Undoubtedly,
some technical challenges remain in ensuring the highest geometric
accuracy in treatment delivery, and solutions may be worthwhile
for the short SABR treatment schemes where inaccuracies during
one fraction cannot easily be compensated in the remaining frac-
tions. Adaptive radiotherapy (ART) to cope with anatomy defor-
mations, particle therapy for reduction of OAR dose delivery and
management of intrafraction motion are sophisticated novel tech-
nologies attracting most attention. ART has shown advantages for
liver SABR in a simulation study,8 and particle therapy has been
investigated for limited numbers of patients.9 Tomosynthesis is
a promising technique where 3D images can be reconstructed over
a limited range of acquisition angles (i.e. a short acquisition
time):10,11 when it becomes clinically available, it would offer
a pragmatic way of monitoring the position of the target during
treatment delivery. Tumour motion tracking for coping with
intrafraction motion has been commercially available for two
decades. While previously limited to dedicated treatment machines
such as the CyberKnife12 and the Vero,13 tumour motion tracking
has recently been delivered on a standard C-arm gantry linear
accelerator.14 Although ART, particle therapy and advanced intra-
fraction motion management may improve treatment accuracy,
there is no clinical evidence that they should constitute a techno-
logical requirement to deliver a high-quality SABR treatment, or
a condition for participation in clinical trials.
So what is the next technical frontier in clinical trials on SABR?
The most likely answer is: quality assurance (QA). Clinical trial
QA is frequently underrated because it is a time-consuming, often
tedious process compared with routine clinical practice, and it
increases the level of documentation. As such, it might discourage
some clinical investigators. Yet, a recent systematic review high-
lighted the importance of clinical trial QA and the link between
protocol violations and treatment outcome:15 in these (non-
SABR) trials, the rate of major radiotherapy deviations ranged
from 11% to 48%. According to the authors, these deviations may
have masked the potential beneﬁts of the treatments investigated
but may also have adversely affected the outcome of individual
patients. Considering the high doses delivered in SABR in only
a few treatment fractions, we argue that a thorough QA pro-
gramme should be of high priority in SABR clinical trials.
Recent SABR clinical trials have embraced this high level of
pre-trial as well as prospective QA with central reviews of
the treatment plans delivered at each institution: these can
include external audit of the output of the linear accelerator
(Transarterial Chemoembolization with Drug-Eluting Beads
versus Stereotactic Body Radiation Therapy for hepatocellular
carcinoma “TRENDY” NCT02470533), central review of the
dose distributions before treatment start (TRENDY), central
approval of the planning target volume margin calculation
recipe (TRENDY) and information about the frequency of
essential quality control checks of image guidance and
respiratory control equipment (“RAS01” NCT01233544). As
an example, the RAS01 trial not only requires the use of “daily
image-guided radiotherapy”, it asks for documentation about
the periodic veriﬁcation of the concordance of the planning
isocentre with the delivery isocentre (“Winston–Lutz” tests)
and the imaging isocentre, as this directly affects the accuracy
of the dose delivery. An overview of SABR QA has recently be
presented by Solberg et al16 and suggests that high-quality
QA instruments are needed to allow high-quality thresholds
in the accreditation of centres interested in trial participation.
For example, because of the high demands on geometrical
accuracy, the distance-to-agreement parameter in dosimetric
g-analyses should be within 2mm, preferentially 1mm as
opposed to the standard of 3mm in non-SABR treatments.
There are still many challenges in SABR clinical trials which
technology cannot directly address. The lack of standards in
normalization and prescription of the heterogeneous dose dis-
tribution is perhaps the clearest example, and guidelines on this
point are being developed. More detailed reporting on dose
distributions not only in the tumour but also in the OARs is
essential to be able to compare results. The present state-of-the-
art technology (four-dimensional CT, cone-beam CT, tracking
etc.) is not SABR speciﬁc and is now widely available: the crucial
point for the next generation of SABR clinical trials is that this
technology will be used correctly and close to its optimal po-
tential for accuracy. The credentialing procedure of SABR needs
to be extensive, but this investment will beneﬁt the trial itself,
the patients and the professionals involved. The ultimate goal is
to achieve a robust trial, with patients treated following pre-
deﬁned criteria for planning and delivery and reported out-
comes that can be compared and/or validated in other
patient groups.
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